These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
474 related articles for article (PubMed ID: 31933152)
1. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer. Liu D Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152 [TBL] [Abstract][Full Text] [Related]
2. The effect of androgen receptor expression on clinical characterization of metastatic breast cancer. Kim JY; Park K; Lee E; Jung HH; Ahn JS; Im YH; Park WY; Park YH Oncotarget; 2017 Jan; 8(5):8693-8706. PubMed ID: 28060723 [TBL] [Abstract][Full Text] [Related]
3. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival. Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151 [TBL] [Abstract][Full Text] [Related]
4. The expression and prognostic role of EBP1 and relationship with AR in HER2+ breast cancer. Liu J; Xu C; Xu D; Cao L; Xue H; Meng Q; Niu Y Virchows Arch; 2020 Aug; 477(2):279-289. PubMed ID: 32086588 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395 [TBL] [Abstract][Full Text] [Related]
6. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction. Liu D; Zhou K Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956 [TBL] [Abstract][Full Text] [Related]
7. A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis. Wang DY; Done SJ; McCready DR; Boerner S; Kulkarni S; Leong WL Breast Cancer Res; 2011 Sep; 13(5):R92. PubMed ID: 21939527 [TBL] [Abstract][Full Text] [Related]
8. Impact of triple negative phenotype on breast cancer prognosis. Kaplan HG; Malmgren JA Breast J; 2008; 14(5):456-63. PubMed ID: 18657139 [TBL] [Abstract][Full Text] [Related]
9. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast. Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653 [TBL] [Abstract][Full Text] [Related]
10. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075 [TBL] [Abstract][Full Text] [Related]
11. [Analysis of prolactin receptor expression in breast cancer subtypes]. Kalinina TS; Kononchuk VV; Sidorov SV; Gulyaeva LF Biomed Khim; 2020 Jan; 66(1):89-94. PubMed ID: 32116231 [TBL] [Abstract][Full Text] [Related]
12. Androgen receptor expression is useful to predict the therapeutic effect in HER2-positive breast carcinoma. Akashi M; Yamaguchi R; Kusano H; Ogasawara S; Abe E; Obara H; Yamaguchi M; Akiba J; Kakuma T; Tanaka M; Akagi Y; Yano H Breast Cancer Res Treat; 2020 Nov; 184(2):277-285. PubMed ID: 32770457 [TBL] [Abstract][Full Text] [Related]
13. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. Sgroi DC; Treuner K; Zhang Y; Piper T; Salunga R; Ahmed I; Doos L; Thornber S; Taylor KJ; Brachtel E; Pirrie S; Schnabel CA; Rea D; Bartlett JMS Breast Cancer Res; 2022 Dec; 24(1):90. PubMed ID: 36527133 [TBL] [Abstract][Full Text] [Related]
14. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers. Micello D; Marando A; Sahnane N; Riva C; Capella C; Sessa F Virchows Arch; 2010 Oct; 457(4):467-76. PubMed ID: 20809337 [TBL] [Abstract][Full Text] [Related]
15. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer? Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210 [TBL] [Abstract][Full Text] [Related]
16. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer. Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268 [TBL] [Abstract][Full Text] [Related]
17. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer. Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648 [TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis. Wu JR; Zhao Y; Zhou XP; Qin X Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575 [TBL] [Abstract][Full Text] [Related]
19. Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers. Witzel I; Graeser M; Karn T; Schmidt M; Wirtz R; Schütze D; Rausch A; Jänicke F; Milde-Langosch K; Müller V J Cancer Res Clin Oncol; 2013 May; 139(5):809-16. PubMed ID: 23392859 [TBL] [Abstract][Full Text] [Related]
20. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies. Kensler KH; Poole EM; Heng YJ; Collins LC; Glass B; Beck AH; Hazra A; Rosner BA; Eliassen AH; Hankinson SE; Winer EP; Brown M; Tamimi RM J Natl Cancer Inst; 2019 Jul; 111(7):700-708. PubMed ID: 30445651 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]